SUMMARY	O

This	O
is	O
a	O
prospective	O
study	O
carried	O
out	O
to	O
determine	O
the	O
outcome	O
of	O
patients	O
who	O
refuse	O
cystectomy	O
after	O
receiving	O
neoadjuvant	O
chemotherapy	O
for	O
muscle	B-Cancer
-	I-Cancer
invasive	I-Cancer
bladder	I-Cancer
cancer	I-Cancer
.	O

Sixty	O
-	O
three	O
patients	O
were	O
evaluated	O
between	O
1995	O
and	O
2001	O
who	O
declined	O
to	O
undergo	O
a	O
planned	O
cystectomy	O
because	O
they	O
achieved	O
a	O
complete	O
clinical	O
response	O
to	O
neoadjuvant	O
cisplatin	O
-	O
based	O
chemotherapy	O
.	O

Herr	O
assessed	O
patient	O
,	O
tumor	B-Cancer
and	O
treatment	O
features	O
for	O
a	O
median	O
follow	O
-	O
up	O
of	O
86	O
months	O
,	O
all	O
patients	O
being	O
followed	O
-	O
up	O
for	O
more	O
than	O
5	O
years	O
.	O

Forty	O
patients	O
(	O
64	O
%	O
)	O
survived	O
,	O
with	O
54	O
%	O
of	O
them	O
having	O
an	O
intact	O
functioning	O
bladder	B-Organ
.	O

The	O
number	O
and	O
size	O
of	O
invasive	B-Cancer
tumors	I-Cancer
were	O
strongly	O
associated	O
with	O
the	O
overall	O
survival	O
.	O

The	O
most	O
significant	O
treatment	O
variable	O
predicting	O
better	O
survival	O
was	O
complete	O
resection	O
of	O
the	O
invasive	B-Cancer
tumor	I-Cancer
on	O
restaging	O
transurethral	O
resection	O
(	O
TUR	O
)	O
before	O
starting	O
chemotherapy	O
.	O

Of	O
23	O
patients	O
(	O
36	O
%	O
)	O
who	O
subsequently	O
died	O
of	O
disease	O
,	O
19	O
(	O
30	O
%	O
)	O
relapsed	O
with	O
invasive	B-Cancer
cancer	I-Cancer
in	O
the	O
bladder	B-Organ
.	O

Over	O
90	O
%	O
of	O
the	O
surviving	O
patients	O
had	O
solitary	O
,	O
small	O
and	O
low	O
-	O
stage	O
invasive	B-Cancer
tumors	I-Cancer
completely	O
resected	O
and	O
83	O
%	O
survived	O
without	O
relapses	O
in	O
the	O
bladder	B-Organ
.	O
[	O
1	O
]	O

